BIOPHARMA DEVELOPMENT AI BY BCG X

Serial Number 98919023
681

Registration Progress

Application Filed
Dec 23, 2024
Under Examination
Approved for Publication
Published for Opposition
Jul 22, 2025
Registered

Attorney Assistance

Important Deadline Approaching
Non-Final Action E-Mailed
Due: August 15, 2025 39 days remaining

Missing this deadline could result in abandonment or cancellation of your trademark.

Basic Information

Serial Number
98919023
Filing Date
December 23, 2024
Published for Opposition
July 22, 2025
Drawing Code
3

Status Summary

Current Status
Active
Status Code
681
Status Date
Jul 2, 2025
Application
Pending
Classes
035 042

Rights Holder

The Boston Consulting Group, Inc.

03
Address
200 Pier 4 Boulevard, Floor 10
Boston, MA 02210

Ownership History

The Boston Consulting Group, Inc.

Original Applicant
03
Boston, MA

Legal Representation

Attorney
Thomas E. Zutic

USPTO Deadlines

Next Renewal Deadline
39 days remaining
Non-Final Action E-Mailed
Due Date
August 15, 2025
Extension Available
Until November 15, 2025

Application History

11 events
Date Code Type Description
Jun 18, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 17, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 17, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 17, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
May 15, 2025 CNRT R NON-FINAL ACTION WRITTEN
May 15, 2025 GNRT F NON-FINAL ACTION E-MAILED
May 15, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 9, 2025 DOCK D ASSIGNED TO EXAMINER
Jan 12, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 12, 2025 MDSM E NOTICE OF DESIGN SEARCH CODE E-MAILED
Dec 23, 2024 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 035
Business consulting and management in the field of clinical trials, namely, management and compilation of computerized databases in the field of clinical trials for business purposes; Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; consulting services regarding cost containment in the field of clinical trials
Class 042
Providing temporary use of online non-downloadable software for business process management; providing temporary use of online non-downloadable generative AI software to assist businesses with clinical trial design, execution, evaluation, and drafting or related reports; providing temporary use of online non-downloadable software to automate document writing for the design, execution, and evaluation of clinical trials; providing temporary use of online non-downloadable software for business management and optimization purposes using technical data, data modelling, AI modelling, and algorithmic processes; providing technical consulting services to businesses in the field of clinical trial optimization, optimizing resource utilization, and improving success rates; providing scientific and technological consulting services for others with regard to the design, planning, management, and optimization of scientific research and clinical trials; consulting services for others in the field of design, planning, and implementation project management of clinical trials

Additional Information

Design Mark
The mark consists of the stacked words "BIOPHARMA , above "DEVELOPMENT AI", which is, in turn, above "BY BCG X", all to the right of a box design containing a circle and two arcs.
Color Claim
Color is not claimed as a feature of the mark.
Pseudo Mark
BIOPHARMA DEVELOPMENT AI BY BOSTON CONSULTING GROUP X

Classification

International Classes
035 042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
BIOPHARMA DEVELOPMENT AI